59971-19-6

Basic information

• Product Name: (E)-2,2'-((hex-3-ene-3,4-diylbis(4,1-phenylene))bis(oxy))diethanol
• Synonyms: (E)-2,2'-((hex-3-ene-3,4-diylbis(4,1-phenylene))bis(oxy))diethanol
• CAS NO: 59971-19-6
• Molecular Weight: 356.462
• Mol File: 59971-19-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-2,2'-((hex-3-ene-3,4-diylbis(4,1-phenylene))bis(oxy))diethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2,2'-((hex-3-ene-3,4-diylbis(4,1-phenylene))bis(oxy))diethanol(59971-19-6)
• EPA Substance Registry System: (E)-2,2'-((hex-3-ene-3,4-diylbis(4,1-phenylene))bis(oxy))diethanol(59971-19-6)

Safety Data

• Hazardous Substances Data: 59971-19-6(Hazardous Substances Data)

Upstream product

• 130-79-0 Diethylstilbestrol dimethyl ether 
• 56-53-1 diethylstilbestrol 
• 6325-57-1 4.4'-bis-ethoxycarbonylmethoxy-α.α'-diethyl-trans-stilbene 

Downstream Products

• 59971-23-2 Methanesulfonic acid 2-(4-{(E)-1-ethyl-2-[4-(2-methanesulfonyloxy-ethoxy)-phenyl]-but-1-enyl}-phenoxy)-ethyl ester 
• 59971-25-4 C₂₂H₂₆Cl₂O₂ 

Relevant articles and documents

Diethylstilbestrol-scaffold-based pregnane X receptor modulators

Due to its function as a regulator of drug-metabolizing enzymes and transporters, pregnane X receptor (PXR) represents an important factor involved in drug metabolism. In this work, we describe the discovery of diethylstilbestrol-based PXR modulators, which were designed from marine sulfated steroids with PXR agonistic activity, solomonsterols A and B, and our recently reported bazedoxifene scaffold-derived PXR antagonists. The methylated diethylstilbestrol derivative 1 displayed potent PXR agonistic activity with an EC50 value of 10.5 μM, whereas compounds 3, 4 and 6 (IC50 for 6 = 27.4 μM) and diethylstilbestrol (2) itself (IC50 = 14.6 μM) exhibited PXR antagonistic effects in HepG2 cells. The PXR modulatory effects of the synthesized diethylstilbestrol derivatives were further confirmed by the induction of PXR-regulated CYP3A4 expression with compound 1, as well as by the inhibition of the rifaximin-promoted up-regulation of CYP3A4 expression with 2 and its derivative 6.